A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Running, not enrolling · Phase 3

Conditions studied: Familial Chylomicronemia Syndrome

In brief

The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.

Key facts

Study ID
NCT05130450
Run by
Ionis Pharmaceuticals, Inc.
People needed
60
Starts
2021-11-18
Expected to finish
2028-02-01
Last updated by the study team
2025-12-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.